Nexium safe for children
This article was originally published in The Tan Sheet
Executive Summary
FDA approves the use of AstraZeneca's prescription proton pump inhibitor Nexium (esomeprazole) for short-term treatment of children 1 to 11 years old for gastroesophageal reflux disease, the agency announces Feb. 28. Providers now can prescribe 10 mg to 20 mg daily doses for children 1 to 11 years old - half of the approved range for 12- to 17-year-olds, FDA says. The agency granted the approval after pediatric safety and pharmacokinetic studies revealed Nexium helped heal esophageal erosions after eight weeks of treatment...
You may also be interested in...
Prilosec OK for young children
FDA approves AstraZeneca's Prilosec (omeprazole) for short-term treatment of symptomatic gastroesophageal reflux disease and erosive esophagitis in children 1 to 2 years old, the agency announced March 20. The label recommends 5 mg or 10 mg daily based on the child's weight. The approval comes less than a month after FDA approved AstraZeneca's proton pump inhibitor Nexium (esomeprazole) for short-term treatment in GERD patients 1 to 11 years old (1"The Tan Sheet" March 3, 2008, In Brief). Procter & Gamble already markets nonprescription omeprazole with Prilosec OTC and Schering-Plough this month filed a switch application with FDA for its PPI/antacid combination Zegerid (20 mg omeprazole/1100 mg sodium bicarbonate) (2"The Tan Sheet" March 17, 2008, In Brief)....
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.